Evidence map›Paper›PMID 20525168›Full record

ArticleRespiratory research2010

Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle.

Hanna M Larner-Svensson, Andrew E Williams, Eleni Tsitsiou, Mark M Perry, Xiaoying Jiang, Kian F Chung, Mark A Lindsay

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Regulatory role of microRNAs in virus-mediated inflammation.Journal of inflammation (London, England) · 2024
    Review
  3. MiRNA-146a-A Key Player in Immunity and Diseases.International journal of molecular sciences · 2023
    Review
  4. Noncoding RNAs in asthmatic airway smooth muscle cells.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Elucidation of the Hdac2/Sp1/Molecular therapy. Nucleic acids · 2021
    Article
  10. Clinico-Pathological Importance of miR-146a in Lung Cancer.Diagnostics (Basel, Switzerland) · 2021
    Review
  11. Prostaglandin EGastroenterology · 2020
    Article
  12. Expression of MiR-140 and MiR-199 in Synovia and its Correlation with the Progression of Knee Osteoarthritis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  13. Aberrant Expression of Immune-related MicroRNAs in Pediatric Patients with Asthma.International journal of molecular and cellular medicine · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Hanna M Larner-SvenssonAirway Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Andrew E Williams
Eleni Tsitsiou
Mark M Perry
Xiaoying Jiang
Kian F Chung
Mark A Lindsay
Imperial College London · GBWythenshawe Hospital · GBUniversity of Manchester · GB

Funding

Wellcome Trust 076111Wellcome Trust 085935
6 · The paper itself

Abstract

backgroundDespite the widespread induction of miR-146a during the innate immune response little is known regarding its biogenesis, function and mechanism. We have therefore examined the role of miR-146a during the interleukin (IL)-1beta-stimulated IL-6 and IL-8 release and proliferation in primary human airway smooth muscle (HASM) cells.

methodsHASM cells were isolated from human lung re-section, cultured to a maximum of 3 - 6 passages and then exposed to IL-1beta. miR-146a expression were determined by qRT-PCR, IL-6 and IL-8 release by ELISA and proliferation using bromodeoxyuridine incorporation. The role of NF-kappaB and the MAP kinase pathways was assessed using pharmacological inhibitors of IKK2 (TPCA-1), JNK (SP600125), p38 MAP kinase (SB203580) and MEK-1/2 (PD98059). miR-146a function was determined following transfection of HASM with inhibitors and mimics using Amaxa electroporation.

resultsIL-1beta induced a time-dependent and prolonged 100-fold induction in miR-146a expression, which correlated with release of IL-6 and IL-8. Exposure to IL-1beta had no effect upon HASM proliferation. Pharmacological studies showed that expression of primary miR-146a was regulated at the transcriptional levels by NF-kappaB whilst post-transcriptional processing to mature miR-146a was regulated by MEK-1/2 and JNK-1/2. Functional studies indicated that IL-1beta-induced miR-146a expression does not negatively regulate IL-6 and IL-8 release or basal proliferation. However, inhibition of IL-1beta-induced IL-6 and IL-8 release was observed at the super-maximal intracellular miR-146a levels obtained by transfection with miR-146a mimics and indicates that studies using miRNA mimics can produce false positive results. Mechanistic studies showed that in the presence of super-maximal levels, the action of miR-146a mimics was mediated at a step following IL-6 and IL-8 mRNA transcription and not through down-regulation of IL-1 receptor associated kinase 1 (IRAK-1) and TNF receptor-associated factor 6 (TRAF6) protein expression, two predicted miR-146a targets involved in IL-1beta signalling.

conclusionsWe have shown that IL-1beta-induced miR-146a expression in HASM and that this was regulated at the transcriptional level by NF-kappaB and at the post-transcriptional level by the MEK-1/2 and JNK-1/2. Unlike previous reports, studies using miRNA inhibitors showed that miR-146a expression did not regulate IL-6 and IL-8 release or proliferation and suggest miR-146a function and mechanism is cell-type dependent.

Indexed as

Immunity, InnateCell ProliferationCells, CulturedDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansI-kappa B KinaseInterleukin-1betaInterleukin-6Interleukin-8JNK Mitogen-Activated Protein KinasesLungMAP Kinase Kinase 1MAP Kinase Kinase 2MicroRNAsMyocytes, Smooth MuscleCXCL8 protein, humanI-kappa B KinaseIKBKB protein, humanIL6 protein, humanInterleukin-1betaInterleukin-6Interleukin-8JNK Mitogen-Activated Protein KinasesMAP2K1 protein, humanMAP2K2 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2MicroRNAsMIRN146 microRNA, humanNF-kappa Bp38 Mitogen-Activated Protein KinasesProtein Kinase Inhibitors

Identifiers

PMID20525168
PMCPMC2894768
OpenAlexW1988261767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.